培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析.doc

《培菲康治疗前后肠易激综合征患者相关肠道益生菌群变化分析.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、培非康治疗刖后肠易激综合征患者相关肠道益生菌群变化分析【摘要】目的观察培菲康治疗前后肠易激综合征(IBS)患者肠道相关益生菌群的变化。方法选取符合罗马m标准的IBS患者60例及年龄、性别相匹配的对照人群20人，IBS患者包括腹泻型、便秘型、混合型、未分型4种类型，再将IBS患者随机分为2亚组，治疗组予以培菲康治疗，2片，3次/d,疗程为4周，对照组予以安慰剂治疗4周，比较治疗前后患者粪便中双歧杆菌和乳杆菌数量的变化。结果腹泻型IBS患者粪便中双歧杆菌及乳杆菌含量均小于正常人群(P<0.01),混合型IBS患者粪便中双歧杆菌含量小于正常人群(P<0.0

2、1);服用培菲康4周后，患者粪便屮双歧杆菌及乳杆菌含量均高于治疗前(P<0.01);以腹泻为主的TBS患者中，治疗有效者，治疗后粪便中双歧杆菌和乳杆菌含量都要少于治疗无效者(P<0.01)o结论IBS患者存在某种肠道菌群的量的变化,且外源性补充相关益生菌制剂时,患者病情的变化伴有粪便中益生菌群的变化。【关键词】肠易激综合征;益生菌;荧光定量PCR;肠道菌群Abstract:Object!veToanalysisofthefecalBifidobacteriumspp.andLactobaci1lusspp・inpatientswithirritabl

3、ebowelsyndrome(IBS)beforeandafteTtreatmentwithbifidtripleviablecapsulesfor4weeks

4、ssifiedgroup・Thepatientsinthediarrheaandconstip&tiongroupsweTefurtherdividedintoti'eatnientgToup(2capsules,3timesdai1yfor4weeks)andthecontrolgroup(placeboadministrationfor4weeks)・ThevariationsinthenumberofthefecalBifidobacteriumspp・andLactobaci1lusspp・wereanalyzedbeforeandaftertheint

5、ervention,usingquantitativeReal-timePCR・ResultslnthelBSpatientswithdiarrhea,theamoimtofBifidobacteriumspp.andLactobaci11usspp・weresmal1erthanthatinhealthypopulation(卩&11;0.01),andintheIBSpatientsofalternatingtype,theamountofBifidobacteriumspp・wassmal1erthanthatinhealthypopulation(卩&1

6、1;0.01).Aweeksafterthetreatnient,theamountsofBifidobacteriumspp.andLactobacillusspp.inallpatientsincreased(卩&It;0.01).Diarrhea-predominantTBSpatientswhohadiniprovenientsintheSymptoinSeverityScoreofIBScarriedsmalleramountsofBifidobacteriumspp・andLactobaci1lusspp・thanpatientswhohadnoim

7、provement・Cone1usionTherearevariationsintheamountsofcertaingutmicrobiota,andwithexogenousreplenishmentofagentsofprobioticmicrobiota,theconditionsofthepatientsvarywiththevariationsoffecalprobioticmicrobiota・Keywordsirritab1ebowe1syndrome;probiotics;fluorescentReal-timePCR;gutmicrobiot

8、a肠易激综合征(irri